MAPT and Alzheimer disease: Consistent with alleviating the primary symptom of AD, VEN-02XX demonstrated potential disease-modifying effects through reductions in neuroinflammation, tau pathology and potentially amyloid pathology, together, resulting in the reshaping of the microglial compartment towards a homeostatic state.